Business
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the interim analysis of efficacy and safety data
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) in IgA nephropathy (IgAN) will be presented in late-breaking trial sessions at both the ISN World Congress of Nephrology in Bangkok, Thailand, March 30-April 2 (ISN-WCN), and NKF Spring Clinical Meetings in Austin, TX, April 11-15, 2023 (NKF). FILSPARI (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), recently received U.S. accelerated approval to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a UPCR ≥1.5 g/g. FILSPARI (sparsentan) is continuing to advance to the two-year confirmatory endpoints in the ongoing PROTECT Study and sparsentan is also in Phase 3 clinical development for the treatment of focal segmental glomerulosclerosis (FSGS). The Company and its collaborators will also present baseline characteristics across patient populations participating in the PROTECT Study, as well as long-term clinical data from the ongoing open-label extension of the Phase 2 DUET Study of sparsentan in FSGS. World Congress of Nephrology, Bangkok, Thailand – March 30-April 2, 2023 Sparsentan Reduces Proteinuria in Patients with Immunoglobulin A Nephropathy (IgAN): Interim Results of the PROTECT StudySession: Late-breaking Clinical TrialsOral Presentation: WCN23-1087 Saturday, April 1, 2:15-3:15 p.m. ICT, Plenary Hall 2-3Poster #: SAT-090 Saturday, April 1, 5-6 p.m. ICT, Ballroom 2-3-4 Immunoglobulin A Nephropathy (IgAN) Patient Baseline Characteristics in Asian versus non-Asian Regions in the Sparsentan PROTECT StudyPoster #: SAT-219Saturday, April 1, 5-6 p.m. ICT, Ballroom 2-3-4 Long-term Efficacy and Safety of Sparsentan in Young Patients with FSGS: 240-week Analysis of the DUET Open Label ExtensionPoster #: SAT-073Saturday, April 1, 5-6 p.m. ICT, Ballroom 2-3-4 NKF Spring Clinical Meetings, Austin, TX – April 11-15, 2023 Rapid and Sustained Proteinuria Reduction with Sparsentan in Immunoglobulin A Nephropathy (IgAN): PROTECT Study Interim ResultsLate-breaking plenary session #333Wednesday, April 12, 5:15-5:45 p.m. CT, Ballroom B Long-term Sparsentan Treatment in Young Patients with FSGS in the DUET Open Label Extension (OLE)Poster #: 326Wedne...